Abstract: Disclosed herein are therapeutic complexes comprising a small-molecule drug complexed with a functional RNA. Further disclosed herein are compositions comprising nanoparticles comprising a carrier polypeptide and a functional RNA molecule complexed with a small-molecule drug, wherein the carrier polypeptide comprises a cell-targeting segment, a cell-penetrating segment, and an oligonucleotide-binding segment, along with methods of making and using such nanoparticles. Further described are methods of treating a subject with a cancer, comprising administering to the subject an effective amount of a composition comprising nanoparticles, the nanoparticles comprising a carrier polypeptide and a functional RNA molecule complexed with a small-molecule chemotherapeutic drug, wherein the carrier polypeptide comprises a cell-targeting segment, a cell-penetrating segment, and an oligonucleotide-binding segment.

Abstract: Novel polypeptide inhibitors of cytoplasmic protein nuclear translocation are disclosed. The inhibitors are comprised of a signal sequence and at least two nuclear localization sequences. The polypeptides are useful as immunosuppression, antiviral and antitumor agents.

Abstract: There is disclosed a structural genus of compounds, defined according to coordinates in three-dimensional space, that binds amino moieties on neighboring lysine residues in a tyrosine residue 29 pocket of the matrix protein component of the HIV preintegration complex (PIC), thereby preventing the PIC from binding to karyopherin .alpha. and preventing nuclear importation and integration of the HIV viral genome into the host cell DNA, thereby preventing viral infection.

Abstract: There is disclosed a genus of compounds that have anti-HIV infection therapeutic activity and inhibit nuclear localization of the HIV preintegration complex.